35results about How to "Less irritating to blood vessels" patented technology

The invention relates to a neo-gambogic acid SLN (solid lipid nanoparticle) and a preparation method thereof. The neo-gambogic acid SLN comprises a therapeutically effective amount of neo-gambogic acid, medicinal phosphatide, a surfactant and a lipid material. In the invention, the neo-gambogic acid is prepared into SLNs (solid lipid nanoparticles), thereby improving the solubility of the neo-gambogic acid, reducing the irritability, improving the bioavailability, and prolonging the action time of medicaments in a human body, in addition, the neo-gambogic acid SLNs can be gathered partially in the human body so as to play the targeted action of the SLNs and exert the anti-cancer therapeutic action of the SLNs better.

The invention provides an etoposide lipidosome used for injection or oral administration. The etoposide lipidosome is characterized in that etoposide is enveloped with phospholipid type substance, and the etoposide lipidosome with small grain size, high entrapment efficiency, good stability and low toxic side effect is prepared. The prepared etoposide lipidosome enhances the solubility and the stability of the etoposide, reduces the toxicity of the etoposide and prolongs the cycling time of the medicine in the blood, thereby improving the therapeutic effect of the medicine; and the preparation prepared by the etoposide lipidosome has the characteristics of low toxicity, low sensitivity and high efficiency on the clinical application. The invention also relates to a preparation method of the etoposide lipidosome, which has simple preparation process and low cost and is suitable for the industrial production.

The invention relates to a flurbiprofen acetaminophen resin lipid microsphere injection, a freeze-drying lipid microsphere injection and a preparation method. Through a reasonable composition proportion and a preparation process with controllable parameters, good stability and strong operability, the flurbiprofen acetaminophen resin which is an indissolvable drug is wrapped in an oil phase and an interfacial film of a lipid microsphere, so that not only is the solubility of the drug remarkably strengthened, but also precipitation and oxidation do not occur easily, the physical and chemical stabilities of the drug are greatly improved, the devitrification phenomenon is avoided in the use and storage processes, a slow release effect is exerted and the action time of the drug in the blood plasma is prolonged, meanwhile, as the lipid microsphere targets to an inflammation part, the toxicity and the vessel stimulation during injection are remarkably reduced, the clinical application of the injections is safer, the treatment effect is more remarkable, and the injections and the methods are suitable for industrialized production and clinical application.

The invention discloses a pharmaceutical composition containing a ganciclovir compound, and a preparation method thereof. The pharmaceutical composition is composed of ganciclovir, polysorbate 80, sodium hydroxide and dextran. The ganciclovir pharmaceutical composition overcomes the irritation of the existing ganciclovir lyophilized powder injections on an injection site, and improves the stability of the ganciclovir lyophilized powder injection and the compliance of patients.

The invention discloses a lipid microsphere injection containing sodium demethyl cantharidate-phosphatide complex and preparation method thereof. The injection comprises the sodium demethyl cantharidate-phosphatide complex, fat-soluble medium, surfactant and other ingredients. In the sodium demethyl cantharidate-phosphatide complex, the molar ratio of sodium demethyl cantharidate to phosphatide is 1-1:10. The prepared sodium demethyl cantharidate-phosphatide complex improves the distribution of sodium demethyl cantharidate in oil-water 2-phase interfacial film and oil phase greatly, increasesthe entrapment efficiency of the medicine in preparation, realizes the interfacial film loading medicine, reduces the toxicity, and can carry out targeting drug release in vivo. The prepared lipid microsphere injection reduces the vascular stimulation of sodium demethyl cantharidate, improves the curative effect, and reduces toxic and side effect.

The invention discloses an alprostadil medium-and-long-chain lipid emulsion for injection and a preparation method thereof, belonging to the technical field of biological medicines. The lipid emulsion is composed of the following components in parts by weight: 0.01-0.1 part of alprostadil, 10-100 parts of long-chain triglycerides, 10-100 parts of medium-chain triglycerides, 1-20 parts of phospholipids, 0.01-1 part of oleic acid, 5-20 parts of glycerol and 300-2500 parts of water for injection. The particle size of the lipid emulsion is 50-200 nm, the lipid emulsion has good stability while the pH value is 5.0-8.0, and the contents of degradation products including prostaglandin A1 and prostaglandin B1 of alprostadil measured by using an HPLC (High Performance Liquid Chromatography) method are respectively below 1%. Compared with traditional alprostadil long-chain lipid emulsions, aqueous-phase alprostadil is significantly decreased, so that the vascular stimulation is reduced, and the liver load is reduced, therefore, the lipid metabolism can be accelerated, and the triglyceride level of plasma can be reduced.

The invention discloses an antihypertensive drug fat milk injection and a preparation method thereof. The antihypertensive drug fat milk injection is a clevidipine butyrate fat milk injection and contains clevidipine butyrate and a pharmacologically acceptable medical excipient; the medical excipient comprises an oil-phase medium, an emulsifier, an osmotic pressure regulator, a stabilizer, a metalcheating agent, a pH value regulator and injection water. The antihypertensive drug fat milk injection has stable quality and high safety and is not irritant to blood vessels.

The present invention discloses a salvianolic acid A injection preparation and the preparation method, the components are salvianolic acid A and pharmaceutical excipients, the present invention is characterized in that the pharmaceutical excipients are vitamin C, the weight ratio of the salvianolic acid A and the vitamin C is 16 to 25 :1, the preferential weight ratio of the salvianolic acid A and the vitamin C is 20:1; the toxicological experiments show that the salvianolic acid A injection preparation of the application has better safety; and the pharmacological experiments indicate that all the groups of the preparation of the application have great pharmacological effects.

The invention belongs to the field of pharmaceutical preparation, and relates to a total bufadienolides solid lipid nanoparticle drug delivery system for injection and a preparation method thereof. Total bufadienolides solid lipid nanoparticles are composed of the components in parts by weight: 0.1-2 parts of total bufadienolides with therapeutically effective amount, 0.5-20 parts of a lipid material, 0.5-15 parts of a lipid soluble emulsifier, 0.5-10 parts of a water soluble emulsifier, 0.002-2.5 part of an antioxidant, 0.1-25 parts of sugar and a proper amount of water for injection. The total bufadienolides solid lipid nanoparticles for injection allow the total bufadienolides to be wrapped in a lipoid nucleus, increase the solubility of the total bufadienolides, reduce the irritation, avoid degradation or leakage of the drug, can achieve targeting effect, controlled release and other effects, and have the advantages of stable physical and chemical properties and the like.

The invention relates to a cyclodextrin inclusion compound containing resibufogenin and a preparation method of the cyclodextrin inclusion compound. The cyclodextrin inclusion compound consists of resibufogenin and an inclusion material at a mole ratio of 1:(1-100), and the preparation method comprises the following steps: dissolving resibufogenin, cyclodextrin and derivatives thereof into a proper amount of a solvent, stirring, and drying, thereby obtaining the cyclodextrin inclusion compound containing resibufogenin. The cyclodextrin inclusion compound containing resibufogenin, provided by the invention, is high in water solubility, low in toxicity, small in blood vessel irritation and high in stability, is capable of ensuring uniformity of preparations, has remarkable anti-tumor functions, is expected to be made into oral tablets, capsules or vein injections, and has great clinical application values.

The invention provides an artemether liposome for injection. The artemether liposome is prepared by adopting an ethanol injection method. The method is simple in preparation process and can be appliedto industrial production. According to the invention, by selecting appropriate material components and adopting appropriate preparation processes, the prepared artemether liposome is small in particle size (150-200nm) and uniform in particle size distribution and has the encapsulation efficiency greater than 90%. The artemether liposome is slowly released in vivo to avoid adverse reactions causedby excessively high concentration of drugs at the initial stage of the injection. Furthermore, the inventor finds that the artemether liposome prepared with the method has high stability, high bioavailability, good resolubility and long storage time, and meets needs of drug use.

The invention belongs to the technical field of medicinal products, and particularly relates to a medicinal composition containing 4-hydroxy-2-oxo-1-pyrrolidine acetamide and application thereof. A 4-hydroxy-2-oxo-1-pyrrolidine acetamide-borneol medicinal composition provided by the invention has a synergistic treatment effect on neuromotor dysfunction and impaired memory dysfunction vascular dementia and senile dementia, and the treatment effect of oxiracetam can be improved remarkably by using borneol, so that the acting dose of oxiracetam is reduced, the dosage is reduced, and adverse reactions are reduced after long-time application. By adopting the medicinal composition, intelligence disturbance of a dementia patient can be treated more effectively, and a treatment effect can be achieved with a small dosage. The medicinal composition is suitable for clinical use.

The invention discloses a pinocembrin and cyclodextrin or cyclodextrin derivative clathrate compound. Cyclodextrin or cyclodextrin derivatives are used for realizing the clathration on pinocembrin, the clathrate compound comprises the pinocembrin and cyclodextrin or cyclodextrin derivatives according to a mol ratio being 1:(1-100). The water solubility of the pinocembrin is improved, the treatment effect of the pinocembrin is more perfectly realized, the clathrate compound is suitable for being used for preparing solid preparations and liquid preparations required in clinics, and the preparations include transfusion, water injection, powder injection, oral liquid, syrup, tablets, capsules, granules and dispersible tablets. The clathrate compound can be used for preparing medicine for preventing and/or treating cardiovascular and cerebrovascular diseases, particularly cerebral apoplexy, and can also be used for preparing medicine for preventing and/or treating germ and/or fungal infection.